Developer docs
API playgroundTry for free, no card

Search company profiles

OOVA

Full company profile

uuid0000doz

Namestring
OOVA
Legal namestring
OOVA, Inc.
Websiteurl
oova.life
Company typeenum
Private
Founded yearint
2019
Descriptiontext

OOVA is a women's health technology company that has developed an at-home hormone monitoring platform combining a proprietary lateral flow immunoassay with AI-powered smartphone scanning. Founded in 2019 and headquartered in New York, the company serves women trying to conceive, women navigating perimenopause, and women seeking general hormone optimization. The core technology quantitatively measures three reproductive hormones — luteinizing hormone (LH), E3G (an estrogen metabolite), and PdG (a progesterone metabolite) — from urine samples, with third-party-validated 99% correlation to blood testing. The platform consists of three test kit SKUs (Fertility, Perimenopause, Hormone Optimization) paired with a companion mobile app that uses computer vision to interpret test strip scans and machine learning to build personalized hormone baselines that improve with continued use. The company has secured 510(k) FDA clearance and developed its assay in collaboration with Mount Sinai physicians.

OOVA operates a dual go-to-market combining direct-to-consumer e-commerce (shop.oova.life, iOS/Android apps) with a B2B healthcare provider channel anchored by the HIPAA-compliant Oova360 dashboard, which delivers real-time patient hormone data to clinicians. Revenue is generated through one-time test kit purchases and the Oova Membership monthly subscription, which bundles a 30% kit discount with 1:1 expert consultations and peer community access. The company has raised $11.5M in total funding, including a $10.3M Series A led by Spero Ventures in June 2023 with participation from Connecticut Innovations, Jefferson Health System, Samsung NEXT's Q Fund, US Fertility, and Virgin Group. Distribution spans 400+ clinics and 600+ providers, with research collaborations at Stanford, UCSF, Mass General, University of Utah Health, and Mount Sinai. The company has earned clinical recognition from ACOG, ASRM, and The Menopause Society, and was awarded the 2026 Nestlé Health Science Innovate Forward Women's Health Challenge.

Short descriptiontext

OOVA is a women's health technology company that has developed an FDA-cleared at-home hormone monitoring platform using AI-powered smartphone scanning of multi-hormone urine test strips, serving women tracking fertility, perimenopause, and hormone optimization via a dual DTC and healthcare provider channel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersNew York, United States
HQ citystring
New York
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
at-home hormone testing, fertility diagnostic kits, hormone monitoring platform, reproductive health technology, perimenopause tracking
Industry3 codes
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAAAE
At-Home Lab Testing & Diagnostics-Integrated Virtual Care
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms
NAICS code2 codes
  • In-Vitro Diagnostic Substance Manufacturing325413
  • Medical and Diagnostic Laboratories62151
SIC code1 code
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Women's Health Diagnostics
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model2 records
1At-Home Hormone Test Kits
TypeOne Time License
Description

One-time purchase of hormone test kits (Fertility, Perimenopause, Hormone Optimization). Test kits are FSA/HSA eligible. The company sells directly through its e-commerce platform.

oova.life
2Oova Membership Subscription
TypeSubscription Recurring
Description

Monthly subscription providing 30% off test kits, peer community access, 1:1 consultations with hormone experts, and member-exclusive events. This is the primary recurring revenue stream.

oova.life
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components1 value
Technology or R&D
Pricing details2 tiers
1One-time kit purchase
ModelUnit PricingBilling cadencePay-as-you-go
Notes

One-time purchase of test kits for Fertility, Perimenopause, or Hormone Optimization tracking

oova.life
2Oova Membership
ModelSubscriptionBilling cadenceMonthly
Notes

Monthly subscription including 30% off test kits, 1:1 consultations with experts, peer community access, and member-exclusive events

oova.life
GTM typeB2B and B2C
B2B and B2C
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

OOVA manufactures at-home hormone diagnostic test kits that quantitatively measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) from urine samples using patented biochemical assay technology. The physical test strips are scanned via a free AI-powered smartphone app that delivers personalized hormone insights and clinical-grade data to users, with a HIPAA-compliant provider dashboard enabling real-time sharing with healthcare providers.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 6 values shown
  • +46% increase in successful pregnancies for fertility patients
+5 more records
Product overview1 text field

Oova is a women's health technology company offering an at-home hormone monitoring platform consisting of test kits and a companion AI-powered smartphone app. The core product portfolio includes the Oova Fertility Hormone Kit and Oova Perimenopause Hormone Kit, which measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine test strips. These kits pair with the free Oova App, which uses computer vision to scan and interpret test results and delivers personalized hormone insights. An optional Oova Membership provides subscription-based access to test kits at a discount plus expert consultations. The Oova360 Provider Dashboard enables healthcare providers to receive real-time patient data, creating a connected ecosystem for fertility tracking and perimenopause management.

Product and service6 records
1Oova Fertility Hormone Kit
CategoryAt-home hormone test kit
Description

An at-home hormone testing kit that quantitatively measures luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine samples to help women identify their fertile window, predict ovulation, and track cycles for conception. The kit pairs with a smartphone app that uses AI image processing to interpret results and provides personalized insights.

2Oova Perimenopause Hormone Kit
CategoryAt-home hormone test kit
Description

An at-home hormone monitoring kit designed for women navigating perimenopause. Measures the same three hormones (LH, E3G, PdG) through urine to help track hormonal fluctuations, map menopause transition stages, and connect symptoms to hormone changes. Provides clinical-grade insights for the menopause transition.

3Oova Hormone Optimization
CategoryAt-home hormone test kit
Description

A tracking experience for women who want to better understand symptoms and hormone patterns at any life stage, not just during perimenopause. Focuses on symptom tracking, hormone insights, and overall wellbeing, allowing users to understand how hormones influence migraines, mood, sleep, energy, and metabolism.

4Oova App
CategoryMobile application
Description

A free AI-powered mobile application that serves as the core platform for all Oova products. The app scans test strips using the smartphone camera, interprets hormone levels through computer vision, provides personalized insights via AI-driven baseline learning, and generates provider-ready reports. Available on iOS and Android.

5Oova Membership
CategorySubscription service
Description

A monthly subscription offering 30% off monthly test kits, access to peer community, 1:1 consultations with hormone experts, and member-exclusive events. Provides a more robust fertility and hormone optimization solution compared to one-time purchases.

6Oova Provider Dashboard (Oova360)
CategoryClinical SaaS platform
Description

A HIPAA-compliant clinician dashboard enabling real-time patient data sharing. Healthcare providers can remotely monitor their patients' ovulation patterns, track treatment progress, and receive hormone data directly from patients' Oova kits.

Scale indicator13 records

Each record includes

Type, Value, Description, Source

Partnership16 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-31
Description

Won Nestlé Health Science's Innovate Forward: Women's Health Challenge. Receives six-month mentorship engagement and membership in the Institute's Food & Nutrition Innovation Council at Tufts University Friedman School.

Strategic tierFlagshipTypeStrategic or Co-development Partner
Description

OOVA technology developed by physicians and biomedical engineers at Mount Sinai. Mt. Sinai physicians developed the patented biochemical assay and OOVA is backed by peer-reviewed science from one of the nation's top medical institutions.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on women's health and hormone monitoring studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaborated on validating urine-serum LH and PdG correlation during IVF stimulation. White paper published on at-home hormone testing against serum standards.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major health system partner using OOVA for patient hormone monitoring. Featured on OOVA's provider page.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major health system partner collaborating on OOVA technology and research.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner studying menstrual cycle and ovulation trends using OOVA's hormone monitoring.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration on hormone monitoring technology and clinical studies.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research partner studying reproductive and hormonal health through OOVA technology.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research partner contributing to clinical studies on hormone monitoring.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic research partner contributing to clinical studies on hormone monitoring.

12Tia
Strategic tierCoreTypeChannel Partner/ Reseller/ Distributor
Description

Women's health clinic partner offering OOVA hormone testing services to their patients as part of care delivery.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Menopause care platform partner offering OOVA technology to their patient population.

14ASRM
Strategic tierCoreTypeStrategic or Co-development Partner
Description

American Society for Reproductive Medicine - OOVA research presented at ASRM conferences, providing clinical credibility and scientific validation.

oova.life
15ACOG
Strategic tierCoreTypeStrategic or Co-development Partner
Description

American College of Obstetricians and Gynecologists - OOVA recognized by ACOG for clinical validation of hormone monitoring technology.

oova.life
Strategic tierCoreTypeStrategic or Co-development Partner
Description

OOVA's perimenopause tracking technology validated by The Menopause Society (formerly NAMS). OOVA research published in ACOG Green Journal.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight7 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Eli Health is developing at-home continuous hormone monitoring via saliva. Emerging player in the same at-home hormone insight category, with overlapping perimenopause and fertility positioning though different sample type.

TypeDirect peer
Description

Inito provides a connected at-home fertility monitor measuring multiple hormones (LH, E3G, PdG) via urine test strips scanned in a smartphone-connected reader. Closely comparable on multi-hormone at-home fertility testing.

TypeBroad incumbent
Description

Modern Fertility, acquired by Ro, offers hormone testing primarily through mail-in blood panels, plus a broader women's health telehealth platform. Comparable target market (women tracking fertility hormones) but different sample type (blood vs. urine) and a much larger parent with broader portfolio.

TypeDirect peer
Description

Proov sells at-home PdG/progesterone test strips and a companion app to confirm ovulation. Direct competitor in the at-home hormone testing category serving women trying to conceive, with overlapping hormone readouts.

TypeEmerging player
Description

Hertility Health provides at-home hormone testing combined with teleconsults for women navigating fertility, perimenopause, and PCOS. Comparable target audience and DTC-plus-clinic model, but operates primarily in the UK and is at earlier stage.

TypeDirect peer
Description

Mira offers at-home quantitative hormone testing (LH, E3G, PdG) for fertility using a connected wand + app. Closest direct competitor to OOVA in the at-home multi-hormone fertility testing category with similar target customer and price point.

TypeBroad incumbent
Description

Clearblue is the established incumbent in at-home ovulation and pregnancy testing. Massive retail distribution and brand recognition in the same consumer category, but uses traditional single-hormone binary tests rather than OOVA's quantitative multi-hormone approach.

TypeBroad incumbent
Description

Labcorp is one of the largest clinical diagnostic laboratories in the US, offering serum hormone testing ordered by physicians. Broad incumbent in the underlying women's reproductive hormone testing market that OOVA is disrupting with at-home urine testing.

9Ro
TypeBroad incumbent
Description

Ro is a multi-vertical telehealth platform (including Roman, Rory, Modern Fertility) covering men's and women's health, including fertility and perimenopause. Broad incumbent with overlapping women's hormone offerings and far greater capital and distribution.

TypeDirect peer
Description

Premom combines ovulation test strips with an AI-driven cycle tracking app. Competes directly on at-home ovulation tracking for women trying to conceive, with lower-cost test strips and a free app versus OOVA's premium positioning.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat6 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers11 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability4 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles4 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors13 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

OOVA

Women's Health Diagnosticsoova.life

OOVA is a women's health technology company that has developed an FDA-cleared at-home hormone monitoring platform using AI-powered smartphone scanning of multi-hormone urine test strips, serving women tracking fertility, perimenopause, and hormone optimization via a dual DTC and healthcare provider channel.

What OOVA does

OOVA is a women's health technology company that has developed an at-home hormone monitoring platform combining a proprietary lateral flow immunoassay with AI-powered smartphone scanning. Founded in 2019 and headquartered in New York, the company serves women trying to conceive, women navigating perimenopause, and women seeking general hormone optimization. The core technology quantitatively measures three reproductive hormones — luteinizing hormone (LH), E3G (an estrogen metabolite), and PdG (a progesterone metabolite) — from urine samples, with third-party-validated 99% correlation to blood testing. The platform consists of three test kit SKUs (Fertility, Perimenopause, Hormone Optimization) paired with a companion mobile app that uses computer vision to interpret test strip scans and machine learning to build personalized hormone baselines that improve with continued use. The company has secured 510(k) FDA clearance and developed its assay in collaboration with Mount Sinai physicians.

OOVA operates a dual go-to-market combining direct-to-consumer e-commerce (shop.oova.life, iOS/Android apps) with a B2B healthcare provider channel anchored by the HIPAA-compliant Oova360 dashboard, which delivers real-time patient hormone data to clinicians. Revenue is generated through one-time test kit purchases and the Oova Membership monthly subscription, which bundles a 30% kit discount with 1:1 expert consultations and peer community access. The company has raised $11.5M in total funding, including a $10.3M Series A led by Spero Ventures in June 2023 with participation from Connecticut Innovations, Jefferson Health System, Samsung NEXT's Q Fund, US Fertility, and Virgin Group. Distribution spans 400+ clinics and 600+ providers, with research collaborations at Stanford, UCSF, Mass General, University of Utah Health, and Mount Sinai. The company has earned clinical recognition from ACOG, ASRM, and The Menopause Society, and was awarded the 2026 Nestlé Health Science Innovate Forward Women's Health Challenge.

OOVA firmographics

Firmographics
Name
OOVA
Legal name
OOVA, Inc.
Website
https://oova.life
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
OOVA is a women's health technology company that has developed an FDA-cleared at-home hormone monitoring platform using AI-powered smartphone scanning of multi-hormone urine test strips, serving women tracking fertility, perimenopause, and hormone optimization via a dual DTC and healthcare provider channel.
Ownership category
akta.pro rank

OOVA industry classification

Industry
Product category
Women's Health Diagnostics
NAICS
In-Vitro Diagnostic Substance Manufacturing (325413), Medical and Diagnostic Laboratories (62151)
SIC
In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAHAOAF
Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Point-of-Care Testing (POCT) & Rapid Diagnostics
SECONDARYHLAHACAL
Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Patient Monitoring, Wearables & Remote Diagnostics
SECONDARYHLALAAAE
At-Home Lab Testing & Diagnostics-Integrated Virtual Care
Healthcare & Life Sciences/Telehealth Platforms/Direct-to-Consumer Virtual Care Platforms

Keywords

  • At-home hormone testing
  • Fertility diagnostic kits
  • Hormone monitoring platform
  • Reproductive health technology
  • Perimenopause tracking

Where OOVA is headquartered

Location

Headquarters

HQ city
New York
HQ country
United States
HQ region
North America

Offices1 record

Markets served

OOVA business model

Business model
GTM type
B2B and B2C
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D

Revenue model

  1. At-Home Hormone Test Kits: One-time purchase of hormone test kits (Fertility, Perimenopause, Hormone Optimization). Test kits are FSA/HSA eligible. The company sells directly through its e-commerce platform.
  2. Oova Membership Subscription: Monthly subscription providing 30% off test kits, peer community access, 1:1 consultations with hormone experts, and member-exclusive events. This is the primary recurring revenue stream.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goOne-time kit purchase
SubscriptionMonthlyOova Membership

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

OOVA product offering

Product offering

Core offering

OOVA manufactures at-home hormone diagnostic test kits that quantitatively measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) from urine samples using patented biochemical assay technology. The physical test strips are scanned via a free AI-powered smartphone app that delivers personalized hormone insights and clinical-grade data to users, with a HIPAA-compliant provider dashboard enabling real-time sharing with healthcare providers.

Product overview

Oova is a women's health technology company offering an at-home hormone monitoring platform consisting of test kits and a companion AI-powered smartphone app. The core product portfolio includes the Oova Fertility Hormone Kit and Oova Perimenopause Hormone Kit, which measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine test strips. These kits pair with the free Oova App, which uses computer vision to scan and interpret test results and delivers personalized hormone insights. An optional Oova Membership provides subscription-based access to test kits at a discount plus expert consultations. The Oova360 Provider Dashboard enables healthcare providers to receive real-time patient data, creating a connected ecosystem for fertility tracking and perimenopause management.

Differentiator

Problem solved

Functional benefit

Products and services

  • Oova Fertility Hormone Kit An at-home hormone testing kit that quantitatively measures luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) through urine samples to help women identify their fertile window, predict ovulation, and track cycles for conception. The kit pairs with a smartphone app that uses AI image processing to interpret results and provides personalized insights.
  • Oova Perimenopause Hormone Kit An at-home hormone monitoring kit designed for women navigating perimenopause. Measures the same three hormones (LH, E3G, PdG) through urine to help track hormonal fluctuations, map menopause transition stages, and connect symptoms to hormone changes. Provides clinical-grade insights for the menopause transition.
  • Oova Hormone Optimization A tracking experience for women who want to better understand symptoms and hormone patterns at any life stage, not just during perimenopause. Focuses on symptom tracking, hormone insights, and overall wellbeing, allowing users to understand how hormones influence migraines, mood, sleep, energy, and metabolism.
  • Oova App A free AI-powered mobile application that serves as the core platform for all Oova products. The app scans test strips using the smartphone camera, interprets hormone levels through computer vision, provides personalized insights via AI-driven baseline learning, and generates provider-ready reports. Available on iOS and Android.
  • Oova Membership A monthly subscription offering 30% off monthly test kits, access to peer community, 1:1 consultations with hormone experts, and member-exclusive events. Provides a more robust fertility and hormone optimization solution compared to one-time purchases.
  • Oova Provider Dashboard (Oova360) A HIPAA-compliant clinician dashboard enabling real-time patient data sharing. Healthcare providers can remotely monitor their patients' ovulation patterns, track treatment progress, and receive hormone data directly from patients' Oova kits.

Quantifiable outcome

  • +46% increase in successful pregnancies for fertility patients
  • +5 more outcomes

Companies that use OOVA

Customer profile

Named customers11 records

Segments4 records

Ideal customer profiles3 records

OOVA technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature6 records

OOVA partnerships and signals

Strategic signal

Partnerships

16 partnerships are on record, tiered core, flagship and minor.

  • Nestlé Health SciencecoreStrategic or Co-development Partner · 31 March 2026Won Nestlé Health Science's Innovate Forward: Women's Health Challenge. Receives six-month mentorship engagement and membership in the Institute's Food & Nutrition Innovation Council at Tufts University Friedman School.
  • Mount Sinai Health SystemflagshipStrategic or Co-development PartnerOOVA technology developed by physicians and biomedical engineers at Mount Sinai. Mt. Sinai physicians developed the patented biochemical assay and OOVA is backed by peer-reviewed science from one of the nation's top medical institutions.
  • Wu Tsai Human Performance AlliancecoreStrategic or Co-development PartnerResearch collaboration on women's health and hormone monitoring studies.
  • New Hope Fertility CentercoreStrategic or Co-development PartnerCollaborated on validating urine-serum LH and PdG correlation during IVF stimulation. White paper published on at-home hormone testing against serum standards.
  • Jefferson HealthcoreStrategic or Co-development PartnerMajor health system partner using OOVA for patient hormone monitoring. Featured on OOVA's provider page.
  • Massachusetts General HospitalcoreStrategic or Co-development PartnerMajor health system partner collaborating on OOVA technology and research.
  • University of Utah HealthcoreStrategic or Co-development PartnerResearch partner studying menstrual cycle and ovulation trends using OOVA's hormone monitoring.
  • Stanford MedicinecoreStrategic or Co-development PartnerResearch collaboration on hormone monitoring technology and clinical studies.
  • UCSFcoreStrategic or Co-development PartnerResearch partner studying reproductive and hormonal health through OOVA technology.
  • University at BuffalominorStrategic or Co-development PartnerAcademic research partner contributing to clinical studies on hormone monitoring.
  • Penn StateminorStrategic or Co-development PartnerAcademic research partner contributing to clinical studies on hormone monitoring.
  • TiacoreChannel Partner/ Reseller/ DistributorWomen's health clinic partner offering OOVA hormone testing services to their patients as part of care delivery.
  • EvernowminorChannel Partner/ Reseller/ DistributorMenopause care platform partner offering OOVA technology to their patient population.
  • ASRMcoreStrategic or Co-development PartnerAmerican Society for Reproductive Medicine - OOVA research presented at ASRM conferences, providing clinical credibility and scientific validation.
  • ACOGcoreStrategic or Co-development PartnerAmerican College of Obstetricians and Gynecologists - OOVA recognized by ACOG for clinical validation of hormone monitoring technology.
  • The Menopause SocietycoreStrategic or Co-development PartnerOOVA's perimenopause tracking technology validated by The Menopause Society (formerly NAMS). OOVA research published in ACOG Green Journal.

Scale indicators13 records

Recent moves6 records

Expansion highlights7 records

OOVA competitors and assessment

Company assessment

Emerging players

  • Eli Health: Eli Health is developing at-home continuous hormone monitoring via saliva. Emerging player in the same at-home hormone insight category, with overlapping perimenopause and fertility positioning though different sample type.
  • Hertility Health: Hertility Health provides at-home hormone testing combined with teleconsults for women navigating fertility, perimenopause, and PCOS. Comparable target audience and DTC-plus-clinic model, but operates primarily in the UK and is at earlier stage.

Direct peers

  • Inito: Inito provides a connected at-home fertility monitor measuring multiple hormones (LH, E3G, PdG) via urine test strips scanned in a smartphone-connected reader. Closely comparable on multi-hormone at-home fertility testing.
  • Proov: Proov sells at-home PdG/progesterone test strips and a companion app to confirm ovulation. Direct competitor in the at-home hormone testing category serving women trying to conceive, with overlapping hormone readouts.
  • Mira: Mira offers at-home quantitative hormone testing (LH, E3G, PdG) for fertility using a connected wand + app. Closest direct competitor to OOVA in the at-home multi-hormone fertility testing category with similar target customer and price point.
  • Premom (Easy@Home): Premom combines ovulation test strips with an AI-driven cycle tracking app. Competes directly on at-home ovulation tracking for women trying to conceive, with lower-cost test strips and a free app versus OOVA's premium positioning.

Broad incumbents

  • Modern Fertility (Ro): Modern Fertility, acquired by Ro, offers hormone testing primarily through mail-in blood panels, plus a broader women's health telehealth platform. Comparable target market (women tracking fertility hormones) but different sample type (blood vs. urine) and a much larger parent with broader portfolio.
  • Clearblue: Clearblue is the established incumbent in at-home ovulation and pregnancy testing. Massive retail distribution and brand recognition in the same consumer category, but uses traditional single-hormone binary tests rather than OOVA's quantitative multi-hormone approach.
  • Labcorp: Labcorp is one of the largest clinical diagnostic laboratories in the US, offering serum hormone testing ordered by physicians. Broad incumbent in the underlying women's reproductive hormone testing market that OOVA is disrupting with at-home urine testing.
  • Ro: Ro is a multi-vertical telehealth platform (including Roman, Rory, Modern Fertility) covering men's and women's health, including fertility and perimenopause. Broad incumbent with overlapping women's hormone offerings and far greater capital and distribution.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

OOVA social profiles

Digital presence

OOVA financial estimates

Financial estimate

Revenue estimate

Valuation estimate

OOVA leadership team

Management profile

Number of profiles

Profiles4 records

OOVA funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors13 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

OOVA M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about OOVA

What does OOVA do?

OOVA manufactures at-home hormone diagnostic test kits that quantitatively measure luteinizing hormone (LH), E3G (estrogen metabolite), and PdG (progesterone metabolite) from urine samples using patented biochemical assay technology. The physical test strips are scanned via a free AI-powered smartphone app that delivers personalized hormone insights and clinical-grade data to users, with a HIPAA-compliant provider dashboard enabling real-time sharing with healthcare providers.

Is OOVA a public or private company?

OOVA is a private company. It is classified as venture growth investor backed and is currently operating.

When was OOVA founded?

OOVA was founded in 2019. It employs 11 to 50 people.

Where is OOVA based?

OOVA is headquartered in New York, United States, in the North America region.

How does OOVA make money?

Two revenue lines are on record. At-Home Hormone Test Kits are the primary driver. The others are oova Membership Subscription.

Who are OOVA's main competitors?

Emerging players on record are Eli Health and Hertility Health. Direct peers are Inito, Proov, Mira and Premom (Easy@Home). Broad incumbents are Modern Fertility (Ro), Clearblue, Labcorp and Ro.

Does OOVA have an API?

No public API is recorded for OOVA.

What industry is OOVA in?

OOVA's product category is Women's Health Diagnostics. Its primary akta.pro industry code is HLAHAOAF, Pregnancy, Fertility & Women’s Health Rapid Tests (hCG, ovulation, vaginal infection), with a secondary code of HLAHACAL, Remote Diagnostics & Home Testing Devices (Connected POC/At-Home Diagnostic Readers). Its NAICS code is 325413 and its SIC code is 2835.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireNew Oova Research with ŌURA Scientists Describes How Menstrual Cycle Hormones Align with Sleep and ReadinessOova and ŌURA presented a pilot study at ASRM 2026 analyzing 375 days of hormone and wearable data from six participants. Sleep and Readiness scores were lowest around the LH surge, with patterns emerging from aligning wearable data to hormone-defined cycle phases. The findings are exploratory and not statistically tested.PR NewswireNew Real-World Data From Oova and Flora Fertility Reveals the Hidden Cost of the Fertility Journey Before Treatment BeginsOova and Flora Fertility released a real-world analysis of 49 users who conceived, finding a median of three tracked cycles and $543 in out-of-pocket costs before treatment. The analysis notes 73% conceived within six months, with some spending over $2,000. The companies are extending research with a follow-up study and employer pilots.PR NewswireOova and Mamaya Health Partner to Connect At-Home Hormone Insights with Specialized Perimenopause Mental Health CareOova, a women's hormone health platform, and Mamaya Health, a women's mental health company specializing in perimenopause care, announced a strategic partnership on July 15, 2026. The partnership enables Oova members to access The Shift, Mamaya's perimenopause-specific mental health program, creating a direct pathway from longitudinal hormone insights to specialized mental health support. Both companies aim to advance a more integrated model of women's healthcare that combines biological data with psychological support for women navigating perimenopause.FittOova Integrates With Oura to Connect Hormone and Biometric DataOova integrated with Oura to combine at-home hormone tests with sleep, recovery, and symptom data. The feature is live in Oova's app, creating a longitudinal health timeline for fertility and perimenopause insights. The partnership adds to Oura's existing integrations with other women's health apps.HomepageOova Integrates with Oura to Connect Hormone Data, Sleep, and Symptom TrackingOova launched an integration with Oura to sync sleep and recovery data with hormone patterns and symptom tracking. The integration aims to help women see correlations between hormonal shifts and sleep quality, mood, and recovery. Oova's research presented at ACOG found significant relationships between estrogen patterns, sleep duration, and anxiety.LinkedInLinkedInOova announced the launch of its integration with ŌURA, enabling Oova users to view sleep, recovery, hormones, and symptoms together on a single timeline within the Oova app. The integration aims to help women understand the 'why' behind data shown by wearables, particularly hormone-related patterns during perimenopause. Oova cited research published with the American College of Obstetricians and Gynecologists showing significant relationships between hormone patterns, sleep, and anxiety.PR NewswireOova Helps Women Make Sense of Their Health Data with New ŌURA IntegrationOova announced a new integration with ŌURA on July 6, 2026, allowing users to sync sleep and recovery data from ŌURA's smart ring directly into the Oova app alongside daily hormone patterns and symptom tracking. The integration enables women to see how hormone fluctuations, symptoms, and sleep patterns interact over time on a single timeline, addressing a gap where most health tools show data streams in isolation. The launch builds on Oova's clinical research presented at ACOG, which found significant relationships between estrogen patterns, sleep duration, and anxiety in women navigating perimenopause.OovaHow to Use Your FSA or HSA to Pay for Hormone Tracking (And Why It Qualifies)Oova, a company specializing in at-home hormone testing kits, has published a guide explaining that its Perimenopause, Fertility, and Hormone Optimization kits qualify as FSA and HSA eligible expenses through a partnership with Truemed, a licensed payment platform that confirms customer eligibility and processes pre-tax health benefit payments.OovaThe 4 Perimenopause Hormone Patterns (And Which One You Have)Oova published its 2025 State of Perimenopause Report drawing on hormone tracking data from over 10,000 women, identifying four distinct perimenopause hormone patterns: Erratic Estrogen, Progesterone-First, Quiet Decline, and Cortisol-Driven, each with unique symptom profiles and treatment implications. The research found that 73% of women sensed hormonal changes 6-18 months before any cycle alterations, and that 40% of women in early perimenopause still had regular cycles, explaining why single-point blood tests frequently fail to detect perimenopause. The article argues that continuous hormone monitoring rather than one-time testing is necessary to identify which pattern a woman is experiencing, as each pattern responds differently to treatment approaches.OovaOova vs. Clearblue Advanced: Which Actually Tracks Fertility?Oova, a quantitative fertility tracking test developed by Oova, has been compared against Clearblue Advanced, a threshold-based test, highlighting key differences in their tracking methodologies and target users. Oova measures LH, E3G, and PdG (progesterone metabolite) to provide numerical hormone concentrations and confirm ovulation occurred, while Clearblue tracks only LH and E3G to deliver binary fertility status indicators. The article, authored by Oova's founder and CEO, positions Oova as better suited for women with PCOS, irregular cycles, or perimenopause, while presenting Clearblue as an appropriate option for women with regular cycles seeking simplicity and affordability.